

REGULATORY **AFFAIRS**

(MPH 104T)



Dr. Vivek S. Tarate
Dr. Upendra C. Galgatte
Dr. Sachinkumar D. Gunjal
Dr. Shilpa S. Kolhe

Kripa Drishti Publications, Pune.

REGULATORY AFFAIRS

(MPH 104T)

Dr. Vivek S. Tarate

Asst. Professor,
Navsahyadri Institute of Pharmacy,
Nasarapur, Pune.

Dr. Upendra C. Galgatte

Associate Professor,
Department of Pharmaceutics,
Modern College of Pharmacy,
Nigdi, Pune.

Dr. Sachinkumar D. Gunjal

Assistant Professor,
Amrutvahini College of Pharmacy,
Sangamner.

Dr. Shilpa S. Kolhe

Assistant Professor,
Vishal Institute of Pharmaceutical Education and Research Ale,
Pune.

Kripa-Drishti Publications, Pune.

Book Title: **Regulatory Affairs (MPH 104T)**

Authored By: **Dr. Vivek S. Tarate, Dr. Upendra C. Galgatte,
Dr. Sachinkumar D. Gunjal, Dr. Shilpa S. Kolhe**

1st Edition

ISBN: **978-81-961210-3-7**



Published: **Feb 2023**

Publisher:



Kripa-Drishti Publications

A/ 503, Poorva Height, SNO 148/1A/1/1A,
Sus Road, Pashan- 411021, Pune, Maharashtra, India.

Mob: +91-8007068686

Email: editor@kdpublications.in

Web: <https://www.kdpublications.in>

© Copyright **Dr. Vivek S. Tarate, Dr. Upendra C. Galgatte, Dr. Sachinkumar D. Gunjal,
Dr. Shilpa S. Kolhe**

All Rights Reserved. No part of this publication can be stored in any retrieval system or reproduced in any form or by any means without the prior written permission of the publisher. Any person who does any unauthorized act in relation to this publication may be liable to criminal prosecution and civil claims for damages. [The responsibility for the facts stated, conclusions reached, etc., is entirely that of the author. The publisher is not responsible for them, whatsoever.]

PREFACE

A Regulatory Affair is a one-of-a-kind collaboration between internal departments of an industry and regulatory bodies that begins with the conceptualization of the product to be developed by that industry and ends with the marketing of that product. It is a crucial and noticeable aspect of pharmaceutical product development. This chapter discusses the regulatory affairs, regulatory requirements for product approval, and documentation in the pharmaceutical industry, with a focus on the master formula record, drug master file, and distribution records.

The book's chapters provide an overview of the regulatory affairs field, information about different regulatory authorities, how these professionals work, and the various roles and responsibilities of regulatory affairs professionals. This book also discusses the various skills required for a career in regulatory affairs, as well as the employment opportunities available in various sectors. We go over typical tasks, required skills, the ins and outs of the submission process, critical knowledge, and much more. Are you drowning in acronyms? We've got your back. Not sure how regulatory plays a role in pharmaceutical development? We describe the procedure.

Following Chapters are including:

1. Documentation in Pharmaceutical industry
2. Regulatory requirement for product approval
3. CMC, post approval regulatory affairs
4. Nonclinical drug development
5. Clinical trials

SCOPE:

Course designed to impart advanced knowledge and skills required to learn the concept of generic drug and their development, various regulatory filings in different countries, different phases of clinical trials and submitting regulatory documents: filing process of IND, NDA and ANDA

- To know the approval process of
- To know the chemistry, manufacturing controls and their regulatory importance
- To learn the documentation requirements for
- To learn the importance and

OBJECTIVES:

Upon completion of the course, it is expected that the students will be able to understand

- The Concepts of innovator and generic drugs, drug development process
- The Regulatory guidance's and guidelines for filing and approval process
- Preparation of Dossiers and their submission to regulatory agencies in different countries
- Post approval regulatory requirements for actives and drug products
- Submission of global documents in CTD/ eCTD formats
- Clinical trials requirements for approvals for conducting clinical trials
- Pharmacovigilance and process of monitoring in clinical trials.

Abbreviations

Abbreviated New Drug Application (ANDA)
Absorption, Distribution, Metabolism, and Excretion (ADME)
Active Implantable Medical Device Category (AIMD)
Active Pharmaceutical Ingredient (API)
Active Pharmaceutical Ingredients (APIs)
Advance Notice of Proposed Rule Making (ANPRM)
Advanced Therapy Medicinal Products (ATMPs)
Agência Nacional de Vigilância Sanitária (ANVISA)
Association of Pharmaceutical Scientists (AAPS)
Australian Register of Therapeutic Goods (ARTG)
Batch Manufacturing Records (BMR)
British Pharmacopoeia (BP)
Carboxymethylcellulose (CMC)
Center for Biologics Evaluation and Research (CBER)
Center for Devices and Radiologic Health (CDER) (CDRH)
Center for Drug Evaluation and Research (CDER)
Central Drugs Standard Control Organization (CDSCO)
central nervous system (CNS)
Change Being Effected (CBE)
chemistry, manufacturing, and control (CMC)
Clinical Trial Applications (CTAs)
Code of Federal Regulations (CFR)
Committee on Genetic Manipulation (RCGM)
Common Good Manufacturing Practise (GMP)
Common Technical Document (CTD)
Common Technical Document (CTD)

Contract Research Organizations (CRO)
Council for International Organizations of Medical Sciences (CIOMS)
Degree of Substitution (DS)
Department of Health and Human Services (DHHS)
Development and Reproductive Toxicology (DART)
Drug Controller General of India (DCGI)
Drug Master File (DMF)
Drug Regulatory Authority (DRA)
Drugs and Health products (DHP)
Electronic Submissions Gateway (ESG)
European Union (EU)
Federal Food, Drug, and Cosmetic Act (FDCA)
Food and Drug Administration (FDA)
General Practice Research Database (GPRD)
Global Harmonization Task Force (GHTF)
Good Clinical Practices (GCP)
Good Laboratory Practice principles (GLP)
Good Laboratory Practices (GLP)
Good Manufacturing Practise (GMP)
Government Publishing Office (GPO)
Health Authority (HA)
Human Factor (HF)
Human Research Ethics Committee (HREC)
Institutional Review Board (IRB)
International Conference of Harmonization (ICH)
International Conference on Harmonization (ICH)
International Conference on Harmonization Good Clinical Practice (ICH-GCP)

Investigational Medicinal Product (IMP)
Investigational Medicinal Product (IMP)
Investigational Medicinal Product Dossier (IMPD)
Investigational Medicinal Products (IMPs)
Investigational New Drug Application (IND)
Investigator's Brochure (IB)
Market Authorization Group (MAG)
Marketing Authorization Applications (MAA)
Marketing Authorization Applications (MAA)
Master Formula Record (MFN)
Material of Construction (MOC)
Monitoring and Compliance Group (MCG)
Mutual Recognition Agreement (MRA)
National Archives and Records Administration's (NARA)
National Institutes of Health (NIH)
New Drug Application (NDA)
Non-Observed Adverse Effect (NOAEL)
Novel Drug Delivery System (NDDS)
Office of Combination Products (OCP)
Office of Regulatory Integrity (ORI)
Office of the Federal Register (OFR)
Pan American Health Organization (PAHO)
Pan American Health Organization (PAHO)
Patient Information Leaflets (PILs)
Pharmaceuticals and Medical Devices Agency (PMDA)
Pharmacodynamics (PD)
Pharmacokinetic/Toxicokinetic (PK/TK)
Pharmacokinetics (PK)

Pharmacovigilance (PV)

Pharmacovigilance Risk Assessment Committee, or PRAC

Post-Marketing Surveillance (PMS)

Prior Approval Supplement (PAS)

Proposed Primary Mode of Action (PMOA)

Public Health Services Act (PHS Act)

Quality Control (QC)

Request-for-Designation (RFD)

Roszdraznadzor (RZN)

Scaleup and Post-Approval Change (SUPAC)

Scale-Up and Post-Approval Changes (SUPAC)

Standard Operating Procedures (SOPS)

United States Pharmacopeia-National Formulary (USP-NF)

US Pharmacopeia (USP)

World Health Organization (WHO)

World Intellectual Property Organization (WIPO)

World Trade Organization (WTO)

INDEX

Unit 1- A	1
1.1 Documentation in Pharmaceutical Industry:.....	1
1.1.1 General Requirement:	2
1.1.2 Importance of Documentation in Pharmaceutical Industry:.....	3
1.1.3 Master Formula Record:.....	5
1.2 Manufacturing:.....	8
1.2.1 Packaging:	8
1.2.2 Drug Master File (DMF):	10
1.2.3 DMF Format and Delivery:	14
1.3 Generic Drugs Product Development Introduction:	16
1.3.1 Generic Drug:	16
1.4 Hatch– Waxman Act and Amendments:	20
1.5 CFR (Code of Federal Regulation):	22
1.5.1 CFR Organization:	22
1.6 ANDA Regulatory Approval Process:	25
1.6.1 ANDA Requirement:	27
1.6.2 NDA Approval Process:	30
1.6.3 BE and Drug Product Assessment:	31
1.7 SUPAC – Scale-Up and Post-Approval Changes:	33
1.7.1 SUPAC guidelines:	34
1.7.2 The Systematic Aspect of SUPAC:	35
1.7.3 Post-Marketing Surveillance:	36
1.8 Outsourcing BA and BE to CRO:	39
1.8.1 Selection of CRO:	40
Unit 1- B.....	42
1.2 Active Pharmaceutical Ingredient (API):	43
1.2.1 Classification of Active Pharmaceutical Ingredient (API):.....	44
1.3 Selection of Reference Biologic:.....	47
1.4 Novel:	48
1.4.1 Novel Drug Delivery Approaches:	48
1.5 Therapies Obtaining NDA:	50
1.5.1 Abbreviated New Drug Application (ANDA):	51
Unit 2.....	53
2.1 CMC:	53
2.1.1 Applications:.....	54
2.1.2 Description:	55

2.1.3 Chemical Structure & Identifiers:	56
2.2 Correct Steps for Dispersing Carboxymethylcellulose Sodium:.....	57
2.2.1 Post Approval Regulatory Affairs:	58
2.2.2 Regulation for Combination Products and Medical Devices	59
2.2.3 Combination Products:	63
2.3 CTD (Common Technical Document):	64
2.3.1 CTD Structure:.....	64
2.3.2 Silent Benefits of the CTD:	65
2.3.3 Limitations of CTD:	65
2.3.4 The CTD dossier is divided into five main modules:.....	66
2.3.5 Benefits of eCTD:	69
2.3.6 COMPARISON of CTD and eCTD:.....	70
2.4 M. Regulatory Requirements of Eu, Tga, Mhra and Row Countries	70
2.4.1 EU:	72
2.5 Guidelines and Scientific Advice:	73
2.5.1 Authorisation and Supervision of Manufacturers:	74
2.6 TGA:	75
2.6.1 Role of TGA:	76
2.6.2 Structure of TGA:	76
2.7 MHRA:	78
2.7.1 Objectives of MHRA:	78
2.7.2 MHRA's Activities:	79
2.7.3 Role of MHRA:.....	80
Unit 3.....	82
3.1 Non Clinical Drug Development:.....	82
3.1.1 Types of Non-Clinical Study	83
3.2 First Dose Estimation in Humans:.....	86
3.3 Global Submission of IND:.....	87
3.2.1 There are Three IND Types:.....	88
3.2.2 Global Submission of NDA:.....	92
3.2.3 Guidance Documents for NDAs:	93
3.2.4 Global Submission of ANDA:.....	95
3.3 Format of an IMPD:	103
3.4 Investigator Brochure (IB):	104
Unit 4.....	111
4.1 Clinical Trials:	111
4.2 Clinical Trial Protocol Development:.....	113
4.4 HIPAA – New, Requirement to Clinical Study Process:.....	121
4.4.1 HIPAA Privacy Rule:.....	121
4.4.2 Pre-Research Review of Medical Records	123
4.4.3 Recruitment:.....	124
4.4.4 Enrollment and Conduct of Study:.....	124

4.4.5 Publication or Presentation of Results:	125
4.5 Study Authorizations:	126
4.6 Pharmacovigilance Safety Monitoring in Clinical Trials:	128
4.6.1 Pharmacovigilance in Clinical Trials:	130
4.6.2 Aim of Pharmacovigilance:	132
4.6.3 Spontaneous ADR Reporting:	132
4.6.4 Prescription Event Monitoring:	133
4.6.5 Electronic Health Records:	133
4.6.6 Need of Pharmacovigilance:	133
5. References.....	136

ABOUT THE AUTHORS



Dr. Vivek S. Tarate

He is presently working as Asst. Professor at Navsahyadri Institute of Pharmacy, Nasarapur, Pune. He has completed M.Pharm in Pharmaceutics from Savitribai Phule Pune University, Pune. He has completed PhD in Naturopathy (Diabetes Reversal) & another PhD (HC) in subject healthcare from Commonwealth University, kingdom of Tonga for his contribution to healthcare sector. He also Completed Certificate and Diploma courses in Naturopathy, Medical Astrology (International Medical Astrologer), Cupping Therapy (TCM – China), Code Blue Trainer (Lincoln University, Malaysia), Nutrition & Diet Planning (FAB Academy, USA) and Regulatory Affairs (IADL, UK approved) from various national & international Universities. He received 1 Indian Patent Grant (Designs) & 4 international Germany utility patent grants. His research works under patent grant process in India and South Africa country. His research interest includes GRDDS, Nanoparticles, Herbal formulations, Type 1 & 2 diabetes reversal. He received 3 copyrights for his value added courses designs. He published review as well as research papers in various UGC Care, Scopus journals. He is a founder of Intellect Institute of Education and Research, Pune. He is also founder of Suvijaya Natural Cure, Satara. He is also working as consultant for Hospitals and Pharma giants. In 2021 he is appointed and upgraded as ILI Paramedic at Hospital & Institute of Integrated Medical Sciences, Chandigarh. He is a fellow member of Screenwriters Association, Mumbai. He is a certified Psychological Counselor. He is also member of Indo-Vietnam medical board and appointed as Network of Influenza Care Expert.



Dr. Upendra C. Galgatte

He is presently working as Associate Professor in Department of Pharmaceutics at Modern College of Pharmacy, Nigdi, Pune. He has completed post-graduation in Pharmaceutics from Rashtrasant Tukdoji Maharaj Nagpur University and doctorate in Pharmaceutical Sciences from Jawaharlal Nehru Technological University, Hyderabad. He has 20 years of experience in academics teaching to undergraduate and postgraduate levels. His research interest includes development of in-situ gels, nasal drug delivery, quantum dots, self-emulsifying drug delivery systems, colloidal drug delivery, fast disintegrating/dissolving oral films, gastro retentive delivery systems, polymer forming matrix delivery. He has been awarded 'Best Teacher Award' by Progressive Education Society, Pune. He is the life-member of different professional bodies viz Indian Pharmaceutical Association, Indian Society for Technical Education, Association of Pharmaceutical Teachers of India, InPharm Association and All India Council for Technical Skill Development. He has more than twenty-seven publications in the technical journals of national and international repute. He has successfully completed sponsored projects of University Grants Commission and Savitribai Phule Pune University. He is approved post graduate teacher in Pharmaceutics at Savitribai Phule Pune University and he has guided more than 45 students for M. Pharm. Dissertation. He is current working as an Editorial Board member of Open Access Journal of Pharmaceutical Research and has reviewed several manuscripts of various national and international journals. He has been resource person for seminars, workshops and conferences. His 2 Indian Patents published and under grant process.



Dr. Sachinkumar D. Gunjal

He is presently working as Assistant Professor at Amrutvahini College of Pharmacy, Sangamner. He has completed B. Pharm. from Bharati Vidyapeeth's Poona College of Pharmacy, Erandwane, Pune (Savitribai Phule Pune University) and M. Pharm from Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune (Savitribai Phule Pune University). He has completed M.B.A. from P.I.R.E.N'S Institute of Business Management and Administration, Loni (Savitribai Phule Pune University). He has completed his PhD. in Pharmaceutics Subject form Savitribai Phule Pune University under guidance of Dr. S. V. Shirolkar sir at Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune. His research work is published in many National and International Journals. He has worked as Assistant Professor at M.A.E.E.R'S Maharashtra Institute of Pharmacy, Pune from December, 2005 to November, 2015. He is a member of Indian Pharmaceutical Association (IPA) and Association of Pharmaceutical Teachers of India (APTI).



Dr. Shilpa S. Kolhe

She is presently working as Assistant Professor at Vishal Institute of Pharmaceutical Education and Research Ale, Pune. She has completed B. Pharm from Savitribai Phule Pune University Pune and M.Pharm in Pharmacognosy from Solapur University. She has completed PhD from Bhagwant University, Ajmer. She published 1 Indian Patent. Her research interest includes phytopharmacy, Nanoparticles, Herbal formulations. She published 3 review as well as 6 research papers in various UGC Care, Scopus journals. She participated in 15 International, national and state level conference and workshop. She also work as evaluator for state level poster presentation competition.



Kripa-Drishti Publications
A-503 Poorva Heights, Pashan-Sus Road, Near Sai Chowk,
Pune – 411021, Maharashtra, India.
Mob: +91 8007068686
Email: editor@kdpublications.in
Web: <https://www.kdpublications.in>

Price: ₹ 399

ISBN: 978-81-961210-3-7



9 788196 121037